■华法林在抗凝治疗中发挥着重要作用,尽管有最新的口服抗凝剂,由于其狭窄的治疗范围和可变的剂量,实现最佳的抗凝治疗具有挑战性。这项研究旨在强调在Medani心脏中心接受华法林治疗的患者的多重用药和药物相互作用。苏丹。
■这项基于医院的回顾性研究于2017年5月至2018年10月进行。收集104名患者的每种并发药物处方,并使用Medscape参考药物相互作用检查器检查药物-药物相互作用。采用SPSS20对数据进行统计分析,并采用描述性统计。
■结果显示,95.2%的患者有三种以上的药物,(3-5),(6-9)和超过10种药物的处方占40.4%,44.2%和10.6%的患者,分别。共有93.3%的患者有药物-药物相互作用,如下:(1-5),(6-10),(11-15),(16-20)和20种以上的药物-药物相互作用被发现在31.7%,32.7%,19.2%,5.8%和3.8%的患者,分别。在88.5%的患者中发现了178种华法林-药物相互作用。13.4%的患者INR在2到2.99之间,在44.2%和21.2%的患者中发现INR值低于2和高于5,分别。镇痛药(n=54;30.3%),心血管药物(n=51;28.6%),抗凝剂(n=46;25.8%)是与华法林相互作用的最常见药物类别。在51%和37.5%的患者中发现了与华法林的重要和严重类型的相互作用,分别。
■这项研究强调了在普遍的多重用药中管理华法林治疗的复杂性。绝大多数患者经历了多种药物相互作用。识别重要和严重的互动强调需要警惕的管理策略,包括改善医疗保健专业人员之间的沟通以及对提供者和患者的有针对性的教育,提高华法林治疗的安全性和有效性。
UNASSIGNED: Warfarin plays an important role in anticoagulation therapy despite the availability of the newest oral anticoagulants, and achieving optimal anticoagulation is challenging due to its narrow therapeutic range and variable dose. This study aimed to highlight polypharmacy and drug interactions in patients receiving warfarin therapy at Medani Heart Centre, Sudan.
UNASSIGNED: This retrospective hospital-based study was conducted from May 2017 to October 2018. Each concurrent medication prescribed for 104 patients was collected and checked for drug-drug interactions using Medscape Reference-Drug Interaction Checker. The data were analysed by using SPSS 20, and descriptive statistics were used.
UNASSIGNED: The results revealed that 95.2% of patients had more than three medications in their profile, (3-5), (6-9) and more than 10 medications were prescribed for 40.4%, 44.2% and 10.6% of patients, respectively. A total of 93.3% of patients had drug-drug interactions, as follows: (1-5), (6-10), (11-15), (16-20) and more than 20 drug-drug interactions were found in 31.7%, 32.7%, 19.2%, 5.8% and 3.8% of patients, respectively. A total of 178 warfarin-drug interactions were identified in 88.5% of the patients. The
INR ranged between 2 and 2.99 in 13.4% of patients, and
INR values below 2 and above 5 were found in 44.2% and 21.2% of patients, respectively. Analgesics (n=54; 30.3%), cardiovascular drugs (n=51; 28.6%), and anticoagulants (n=46; 25.8%) were the most common drug classes that interact with warfarin. Significant and serious types of interactions with warfarin were found in 51% and 37.5% of patients, respectively.
UNASSIGNED: This study highlights the complexity of managing warfarin therapy amid prevalent polypharmacy. A substantial majority of patients experienced multiple drug interactions. The identification of significant and serious interactions emphasizes the need for vigilant management strategies, including improved communication among healthcare professionals and targeted education for both providers and patients, to enhance the safety and efficacy of warfarin therapy.